MEI Pharma https://investor.meipharma.com/ MEI Pharma Reports First Quarter Fiscal Year 2019 Results and Operational Highlights https://investor.meipharma.com/2018-11-08-MEI-Pharma-Reports-First-Quarter-Fiscal-Year-2019-Results-and-Operational-Highlights -- MEI on Track to Initiate ME-401 Phase 2 Accelerated Approval Study Around Year-End -- Thu, 08 Nov 2018 13:00:00 -0800 https://investor.meipharma.com/2018-11-08-MEI-Pharma-Reports-First-Quarter-Fiscal-Year-2019-Results-and-Operational-Highlights MEI Pharma To Present at Stifel 2018 Healthcare Conference https://investor.meipharma.com/2018-11-06-MEI-Pharma-To-Present-at-Stifel-2018-Healthcare-Conference Tue, 06 Nov 2018 05:00:00 -0800 https://investor.meipharma.com/2018-11-06-MEI-Pharma-To-Present-at-Stifel-2018-Healthcare-Conference MEI Pharma and Kyowa Hakko Kirin Announce License Agreement to Develop and Commercialize ME-401 in Japan https://investor.meipharma.com/2018-11-05-MEI-Pharma-and-Kyowa-Hakko-Kirin-Announce-License-Agreement-to-Develop-and-Commercialize-ME-401-in-Japan MEI to Receive $10 Million Upfront Payment, Plus Milestones and Tiered Royalty Payments Mon, 05 Nov 2018 05:00:00 -0800 https://investor.meipharma.com/2018-11-05-MEI-Pharma-and-Kyowa-Hakko-Kirin-Announce-License-Agreement-to-Develop-and-Commercialize-ME-401-in-Japan MEI Pharma to Present Clinical Data from Three Oncology Programs at the 2018 American Society of Hematology (ASH) Annual Meeting https://investor.meipharma.com/2018-11-01-MEI-Pharma-to-Present-Clinical-Data-from-Three-Oncology-Programs-at-the-2018-American-Society-of-Hematology-ASH-Annual-Meeting Thu, 01 Nov 2018 06:00:00 -0700 https://investor.meipharma.com/2018-11-01-MEI-Pharma-to-Present-Clinical-Data-from-Three-Oncology-Programs-at-the-2018-American-Society-of-Hematology-ASH-Annual-Meeting MEI Pharma and BeiGene Announce Clinical Collaboration to Evaluate ME-401 in Combination with Zanubrutinib in Patients with B-Cell Malignancies https://investor.meipharma.com/2018-10-11-MEI-Pharma-and-BeiGene-Announce-Clinical-Collaboration-to-Evaluate-ME-401-in-Combination-with-Zanubrutinib-in-Patients-with-B-Cell-Malignancies Thu, 11 Oct 2018 03:00:00 -0700 https://investor.meipharma.com/2018-10-11-MEI-Pharma-and-BeiGene-Announce-Clinical-Collaboration-to-Evaluate-ME-401-in-Combination-with-Zanubrutinib-in-Patients-with-B-Cell-Malignancies